Pharma and Profits
Pharma and Profits
Balancing Innovation, Medicine, and Drug Prices
LaMattina, John L.
John Wiley & Sons Inc
09/2022
112
Mole
Inglês
9781119881339
15 a 20 dias
190
Introduction x
Chapter 1 The $1000 Pill: the Fiscal Consequences of Curing Hepatitis C 1
Chapter 2 Enter the Payers: Fda Approval Does Not Guarantee Commercial Success 10
Chapter 3 Pandemic: mRNA Vaccines And The Race For A Cure 19
Chapter 4 Federal Investment in R&d: Why the Government Does Not Deserve a Piece of Biopharma's Profits? 34
Chapter 5 Insulin: the True Cost of a 100- Year- Old Drug 44
Chapter 6 The Costly Alzheimer's Disease Drug: a Questionable Breakthrough 50
Chapter 7 Gene Therapy: How Much Is a Life Worth? 60
Chapter 8 Proving the Value of Expensive Drugs: Should We Pay For Drugs Whose Ultimate Value Is Unknown? 70
Chapter 9 Generic Drugs: Built- in Cost Controls 74
Chapter 10 About Those Soaring Pharma Profits: Are They Driving Healthcare Costs? 80
Chapter 11 Schemes to Lower Drug Prices: the Impact of Reduced Resources on R&d 84
Final Thoughts 96
Index 98
Introduction x
Chapter 1 The $1000 Pill: the Fiscal Consequences of Curing Hepatitis C 1
Chapter 2 Enter the Payers: Fda Approval Does Not Guarantee Commercial Success 10
Chapter 3 Pandemic: mRNA Vaccines And The Race For A Cure 19
Chapter 4 Federal Investment in R&d: Why the Government Does Not Deserve a Piece of Biopharma's Profits? 34
Chapter 5 Insulin: the True Cost of a 100- Year- Old Drug 44
Chapter 6 The Costly Alzheimer's Disease Drug: a Questionable Breakthrough 50
Chapter 7 Gene Therapy: How Much Is a Life Worth? 60
Chapter 8 Proving the Value of Expensive Drugs: Should We Pay For Drugs Whose Ultimate Value Is Unknown? 70
Chapter 9 Generic Drugs: Built- in Cost Controls 74
Chapter 10 About Those Soaring Pharma Profits: Are They Driving Healthcare Costs? 80
Chapter 11 Schemes to Lower Drug Prices: the Impact of Reduced Resources on R&d 84
Final Thoughts 96
Index 98